FGL vs N-Acetyl Semax Amidate
A side-by-side research comparison of FGL and N-Acetyl Semax Amidate across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | FGL | N-Acetyl Semax Amidate |
|---|---|---|
| Full name | FGL (NCAM-Derived Peptide) | N-Acetyl Semax Amidate (NA Semax) |
| Category | Cognitive & Nootropic | Cognitive & Nootropic |
| Status | Research compound | Research compound |
| Mechanism | Mimics NCAM FG loop interacting with FGFR1 to promote LTP, neurite outgrowth, neuronal survival, and presynaptic function enhancement. | A heptapeptide analog of ACTH(4-10) that increases BDNF and NGF expression, modulates the dopaminergic and serotonergic systems, and provides neuroprotective and pro-focus effects. The acetyl/amidate modifications extend its half-life versus plain Semax. |
| Molecular weight | ~1,800 Da | ~900 Da |
| Half-life | 4-8 hours | Longer than base Semax (modifications resist peptidases) |
| Bioavailability | Moderate (SubQ, partial BBB crossing) | Intranasal (primary); subcutaneous also used |
| Typical dose | 1-5 mg/kg (research) | ~300-600 mcg per day |
| Frequency | Daily or every other day | 1-2x daily |
| Route | Subcutaneous | Intranasal spray/drops |
FGL reported benefits
- Synaptic plasticity
- LTP facilitation
- Memory improvement
- Neurotrophic effects
- FGFR activation
N-Acetyl Semax Amidate reported benefits
- Improved focus and mental clarity
- Raises BDNF/NGF (neurotrophic)
- Neuroprotective
- Longer-acting than base Semax
Related comparisons
Research and educational reference only. Not medical advice.